Results 11 to 20 of about 788,607 (367)

Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa. [PDF]

Int J Lab Hematol, 2021
Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations.
Bourdin M, Perrotin D, Mathieu O, Herve T, Depasse F, Lu G, Conley PB, Contant G.   +7 more
europepmc   +2 more sources

Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors [PDF]

OTA International, 2023
. Objectives:. Geriatric patients who sustain hip fractures and are taking factor Xa inhibitors (Xa-I) experience surgical delay. Our institution developed a pharmacokinetic protocol to formally guide and expedite surgical timing for these patients.
Juntian Wang, MD, Paal Nilssen, BS, Julia Stone, BS, Kathleen Breda, MSN, BBA, RN, AGACNP-BC, ONP-C, Milton Little, MD, Charles Moon, MD, Carol Lin, MD   +6 more
doaj   +2 more sources

Efficacy and Toxicity of Factor Xa Inhibitors

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle   +4 more
doaj   +6 more sources

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring [PDF]

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +2 more sources

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis [PDF]

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +2 more sources

Application of Molecular Modeling to Development of New Factor Xa Inhibitors [PDF]

BioMed Research International, 2015
In consequence of the key role of factor Xa in the clotting cascade and absence of its activity in the processes that do not affect coagulation, this protein is an attractive target for development of new blood coagulation inhibitors.
Alexey V. Sulimov, Danil C. Kutov, Ekaterina V. Katkova, Elena I. Sinauridze, Fazoil I. Ataullakhanov, Irina V. Gribkova, Khidmet S. Shikhaliev, Maria P. Kochugaeva, Michael Yu. Krysin, Svetlana M. Medvedeva, Vladimir B. Sulimov   +10 more
core   +4 more sources

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Medicine
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen   +4 more
doaj   +2 more sources

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]

Scientific Reports
Direct oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano, Shiro Adachi, Miku Hirose, Takeshi Adachi, Itsumure Nishiyama, Kenichiro Yasuda, Masahiro Yoshida, Takahisa Kondo, Toyoaki Murohara   +8 more
doaj   +2 more sources

Reversing factor Xa inhibitors - clinical utility of andexanet alfa [PDF]

Journal of Blood Medicine, 2017
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal ...
Bhansali, Hardik, Gibbs, Joseph J, Kaatz, Scott, Lavender, Robert, Mahan, Charles E, Paje, David G   +5 more
core   +3 more sources

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +2 more sources